Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
6,235,531
-
Total 13F shares
-
17,417,079
-
Share change
-
+3,894,966
-
Total reported value
-
$324,965,795
-
Put/Call ratio
-
67%
-
Price per share
-
$18.66
-
Number of holders
-
96
-
Value change
-
+$71,330,482
-
Number of buys
-
51
-
Number of sells
-
38
Institutional Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) as of Q1 2023
As of 31 Mar 2023,
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) was held by
96 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
17,417,079 shares.
The largest 10 holders included
FMR LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., STATE STREET CORP, BlackRock Inc., WELLINGTON MANAGEMENT GROUP LLP, VANGUARD GROUP INC, Artemis Investment Management LLP, DRIEHAUS CAPITAL MANAGEMENT LLC, GEODE CAPITAL MANAGEMENT, LLC, and MASSACHUSETTS FINANCIAL SERVICES CO /MA/.
This page lists
96
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.